Cabozantinib (Cabometyx)
نویسندگان
چکیده

 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class.
 The inform non-binding recommendations that help guide decisions Canada's federal, provincial, territorial governments, with exception Quebec.
 This review assesses cabozantinib (Cabometyx), tablets, 20 mg, 40 60 mg oral.
 Indication: For treatment adult patients locally advanced metastatic differentiated thyroid carcinoma (DTC) has progressed following prior VEGFR-targeted therapy who radioactive iodine-refractory ineligible.
منابع مشابه
CCR Translations: CCR-13-2636 RE: Dai et al. “Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.” Title: Cabozantinib and prostate cancer: inhibiting seed and disrupting soil? Running title: Cabozantinib and prostate cancer metastasis
RE: Dai et al. " Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. " Title: Cabozantinib and prostate cancer: inhibiting seed and disrupting soil? Running title: Cabozantinib and prostate cancer metastasis Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
متن کاملCabozantinib and prostate cancer: inhibiting seed and disrupting soil?
Treatment with cabozantinib, an inhibitor of MET and VEGFR2 signaling, has demonstrated clinical benefit in early trials in men with metastatic prostate cancer. Preclinical evidence suggests that cabozantinib can kill cancer cell seeds while disrupting angiogenesis and stromal cells in the metastatic soil.
متن کاملCutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.
IMPORTANCE Cabozantinib S-malate is a vascular endothelial growth factor receptor 2, c-MET, and RET multitargeted tyrosine kinase inhibitor that has antiangiogenic and antitumorigenic properties with potential efficacy for the treatment of several cancers. Cutaneous reactions, one of the most frequently observed adverse effects associated with tyrosine kinase inhibitors, can significantly affec...
متن کاملModulation of cabozantinib efficacy by the prostate tumor microenvironment
The tumor microenvironment (TME) is increasingly recognized as the arbiter of metastatic progression and drug resistance in advanced prostate cancer (PCa). Cabozantinib is a potent tyrosine kinase inhibitor (TKI) with reported biological activity in the PCa epithelia, but failed to provide an overall survival benefit in phase 3 clinical trials. However, the promising biologic efficacy of the dr...
متن کاملEffect of cabozantinib on CYP450 isoforms activity of rats
Cabozantinib S-malate is a vascular endothelial growth factor receptor 2, c-MET, and RET multi-targeted tyrosine kinase inhibitor that has antiangiogenic and antitumorigenic properties with potential efficacy for the treatment of several cancers. In order to investigate the effects of cabozantinib on the metabolic capacity of cytochrome P450 (CYP) enzymes, a cocktail method was employed to eval...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian journal of health technologies
سال: 2023
ISSN: ['2563-6596']
DOI: https://doi.org/10.51731/cjht.2023.553